According to Iris Lugo Carro, the clinical trials being carried out by Cuban scientists and Abivax – involving 230 patients from eight Asian countries, and the participation of 50 clinical centers – are being realized under regulation ABX 203.
To date, the study has been approved by the regulatory authorities of Australia, New Zealand, Singapore, South Korea, Taiwan, Hong Kong, the Philippines and Thailand.
迄今为止,研究已获得澳大利亚,新西兰,新加坡,韩国,台湾,香港,菲律宾和泰国的监管当局。
The trials were designed by high-level sector experts contracted by Abivax, in collaboration with Cuban scientists.
该试验是由Abivax与古巴科学家签约,合作高级别部门的专家设计的。
Satisfactory progress is being made in the investigation being carried out in this region of the world, where Hepatitis Bprevalence ishighest.
The chronic liver disease, caused by the hepatitis B (HBV) virus, is one of the principal causes of liver cancer, cirrhosis of the liver and other illnesses such as ascites, esophageal varices, splenomegaly, all with high mortality rates.
HBV causes almost one million deaths every year, according to statistics from the World Health Organization (WHO).
乙肝病毒引起将近一万人死亡,每年,据世界卫生组织(WHO)的统计数据。
HeberNasvac contains the surface and nucleocapsid antigen of the hepatitis B virus, two recombinant proteins manufactured by CIGB.
The therapeutic treatment is either injected or administered nasally, causes fewer adverse reactions and is a more effective antiviral remedy than existing treatments.
HeberNasvac含有乙型肝炎病毒的表面和核衣壳抗原,两种重组蛋白质制造的CIGB。
治疗性治疗要么注射或经鼻给药,引起不良反应少,是一种更有效的抗病毒补救比现有的治疗方法。
A second study is underway in Cuba with the participation of the Ministry of Public Health, in order to optimize the virus treatment plan and find new ways to administer the product.
第二项研究正在进行古巴公共卫生部的参与,以优化病毒治疗方案,并寻找新的方法来管理产品。
Involved in this study are 13 clinics across the entire country, which will benefit 160 Cuban patients. The investigation is currently in the recruitment stage, to find suitable patients suffering from the virus to participate.
The CIGB anticipates that HeberNasvac could be made available in Cuba in 2016, after it secures approval from the health register granted by the State Control of Medicines, Equipment and Medical Devices Center.
The HeberNasvac therapeutic medication is supported by patents granted in the most demanding markets.
CIGB scientists, in collaboration with the University of Ehime, Japan; the Bangladesh Liver Foundation and Liver Research Society; the Pasteur Institute in France; the Venezuelan Institute of Scientific Research and the University of Hannover in Germany, have published more than 20 scientific works relating to the product.